Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: Clin Cancer Res. 2014 Mar 17;20(10):2783–2792. doi: 10.1158/1078-0432.CCR-13-2364

Figure 1.

Figure 1

Goodness-of-fit plots from the bevacizumab population pharmacokinetic model (model parameterization [B]). A, Observed versus individual predicted concentrations for the covariate-free (base structural) model. B, Conditional weighted residual (CWRES) versus time in days for the covariate-free model with LOWESS (solid line). C, Observed versus population predicted concentrations for the covariate-free model. D, Observed versus population predicted concentrations for the final population model. Dashed lines in panel A, C, and D represent the line of unity.